Table III.
Immunological parameters and autoantibodies of the patients
| Parameter | Case 1 | Case 2 | Reference range |
|---|---|---|---|
| CD3+ [%; cells/μl] | 53.9; 1935 | 71.6; 990 | 66 –76; 1,400– 2,000 |
| CD4+ [%; cells/μl] | 28.9; 1038 | 40.44; 560 | 33 –41; 700– 1,100 |
| CD8+ [%; cells/μl] | 27.6; 991 | 22.3; 310 | 27 –35; 600–900 |
| CD4/CD8 [%; cells/μl] | 1.05 | 1.81 | 1.1–1.4 |
| CD19+ [%; cells/μl] | 8; 287 | 17.0; 240 | 2 –22; 300–500 |
| IgG [g/l] | 11.4 | 10.11 | 7.23–16.82 |
| IgA [g/l] | 2.01 | 1.19 | 0.69–3.82 |
| IgM [g/l] | 1.12 | 1.25 | 0.63–2.7 |
| IgE [IU/ml] | 12.1 | 3314 | < 80 |
| Antinuclear antibodies (ANA) | < 1:100 | 1:1000 | < 1:100 |
| ANA profile tests (IgG antibody) | |||
| Anti-nRNP/Sm | Negative | Negative | Negative |
| Anti-Smith | Negative | Negative | Negative |
| Anti-RNP 70 | Negative | Positive | Negative |
| Anti-SS-A | Negative | Negative | Negative |
| Anti-Ro-52 | Negative | Negative | Negative |
| Anti-SS-B | Negative | Negative | Negative |
| Anti-Scl-70 | Negative | Negative | Negative |
| Anti-CEN pB | Negative | Negative | Negative |
| Anti-PCNA | Negative | Borderline | Negative |
| Anti-dsDNA | Negative | Negative | Negative |
| Anti-nucleosomes | Negative | Negative | Negative |
| Anti-AMA-M2 | Negative | Negative | Negative |
| Myositis autoantibodies (IgG, U/l) | Interpretation | ||
| Anti-Mi-2 | 0.54 | Not available | < 0.30 – negative 0.3–0.8 – borderline 0.8 < 4.50 – low positive 4.5–10 – positive > 10 – high positive |
| Anti-PM/Scl complex | 0.15 | Negative | |
| Anti-histidyl-tRNA synthetase (Jo1) | < 0.15 | Negative | |
| Anti-signal recognition particle 54 (SRP 54) | 0.36 | Not available | |
| Anti-threonyl-tRNA synthetase (PL-7) | 0.18 | Not available | |
| Anti-alanyl-tRNA synthetase (PL-12) | 0.71 | Not available | |
| Anti-Ku | < 0.15 | Not available | |